{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:37Z","timestamp":1793237677405,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009992","name":"Seattle Children's Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018762","name":"Seattle Children's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031795","name":"GentiBio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ymthe.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:38:12Z","timestamp":1773419892000},"page":"4035-4053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical efficacy and safety assessment of engineered regulatory T cells for treatment of IPEX and other autoimmune disorders"],"prefix":"10.1016","volume":"34","author":[{"given":"Yuchi","family":"Honaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle P.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Scharffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iram F.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy R.","family":"Torgerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Allenspach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cade Ellis K.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene I.","family":"Uenishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Cost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-1776","authenticated-orcid":false,"given":"David J.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.03.017_bib1","article-title":"The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities","volume":"11","author":"Bayati","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cei\/uxac078","article-title":"Regulatory T-cell therapy approaches","volume":"211","author":"McCallion","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib3","article-title":"Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective","volume":"10","author":"Amini","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166135","article-title":"Opportunities for Treg cell therapy for the treatment of human disease","volume":"14","author":"Bluestone","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.03.017_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.03.017_bib7","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.ymthe.2023.04.021","article-title":"A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells","volume":"31","author":"Cook","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.017_bib8","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2023.07.016","article-title":"Dual-locus, dual-HDR editing permits efficient generation of antigen-specific regulatory T cells with robust suppressive activity","volume":"31","author":"Hunt","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.017_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171844","article-title":"GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes","volume":"9","author":"Uenishi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.03.017_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0022-3476(82)80573-8","article-title":"An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy","volume":"100","author":"Powell","year":"1982","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.03.017_bib11","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1172\/JCI11679","article-title":"JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome","volume":"106","author":"Chatila","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.03.017_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.03.017_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fimmu.2012.00211","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity","volume":"3","author":"Barzaghi","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2023.11.021","article-title":"IPEX syndrome from diagnosis to cure, learning along the way","volume":"153","author":"Bacchetta","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","article-title":"Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study","volume":"141","author":"Barzaghi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s10875-012-9684-1","article-title":"Multiple reversions of an IL2RG mutation restore T cell function in an X-linked severe combined immunodeficiency patient","volume":"32","author":"Kawai","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clim.2009.12.011","article-title":"Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants","volume":"135","author":"Davis","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783022","article-title":"Reversion Mosaicism in Primary Immunodeficiency Diseases","volume":"12","author":"Miyazawa","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41424-018-0064-x","article-title":"Clinical Heterogeneity of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome: A French Multicenter Retrospective Study","volume":"9","author":"Duclaux-Loras","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib20","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/j.jaip.2020.04.070","article-title":"Clinical, Immunological, and Genetic Features in Patients with Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndrome","volume":"8","author":"Jamee","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.ymthe.2026.03.017_bib21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.bios.2007.12.009","article-title":"A novel electroporation method using a capillary and wire-type electrode","volume":"23","author":"Kim","year":"2008","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.ymthe.2026.03.017_bib22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpeds.2005.04.017","article-title":"Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome)","volume":"147","author":"Bindl","year":"2005","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.03.017_bib23","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2019.11.043","article-title":"Treatment with rapamycin can restore regulatory T-cell function in IPEX patients","volume":"145","author":"Passerini","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1208\/s12248-008-9038-3","article-title":"Assessment of the impact of dosing time on the pharmacokinetics\/pharmacodynamics of prednisolone","volume":"10","author":"Xu","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ymthe.2026.03.017_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40272-019-00337-7","article-title":"Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature","volume":"21","author":"Bevacqua","year":"2019","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ymthe.2026.03.017_bib26","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1056\/NEJM200106073442304","article-title":"Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation","volume":"344","author":"Baud","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.017_bib27","article-title":"Umbilical cord blood derived cellular therapy: advances in clinical development","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.03.017_bib29","article-title":"Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus","volume":"1","author":"Singh","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.03.017_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo5407","article-title":"FOXP3 exon 2 controls T(reg) stability and autoimmunity","volume":"7","author":"Du","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.752394","article-title":"Co-Expression of FOXP3FL and FOXP3Delta2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function","volume":"12","author":"Sato","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/eji.202149210","article-title":"Towards gene therapy for IPEX syndrome","volume":"52","author":"Borna","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/imr.13289","article-title":"FOXP3 deficiency, from the mechanisms of the disease to curative strategies","volume":"322","author":"Borna","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.03.017_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg6822","article-title":"Identification of unstable regulatory and autoreactive effector T cells that are expanded in patients with FOXP3 mutations","volume":"15","author":"Borna","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.03.017_bib35","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/bloodadvances.2020003219","article-title":"First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings","volume":"5","author":"MacMillan","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2026.03.017_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1214","article-title":"Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses in vivo","volume":"9","author":"Sato","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2025.01.045","article-title":"Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer","volume":"33","author":"Du","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.017_bib38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41587-022-01418-8","article-title":"High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails","volume":"41","author":"Shy","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib39","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41587-024-02504-9","article-title":"Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration","volume":"43","author":"Xie","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.03.017_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102568","article-title":"Single-stranded HDR templates with truncated Cas12a-binding sequences improve knock-in efficiencies in primary human T cells","volume":"36","author":"Nitulescu","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.03.017_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5530","article-title":"Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template","volume":"7","author":"Sather","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.03.017_bib42","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.03.017_bib43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:25:44Z","timestamp":1793237144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1525001626002029"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical efficacy and safety assessment of engineered regulatory T cells for treatment of IPEX and other autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}